Capital One Initiates Coverage On Fennec Pharmaceuticals with Overweight Rating, Announces Price Target of $11
Capital One analyst Naureen Quibria initiates coverage on Fennec Pharmaceuticals (NASDAQ:FENC) with a Overweight rating and announces Price Target of $11.
Bluebird bio Seeks Back-to-Back Nods, ‘Go’ or ‘No-Go’ For Revance’s Botox Rival, Amylyx’ Twin Hurdles And More: September’s Key PDUFA Catalysts Biotech Investors Must Know
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.
Fennec Pharma to Receive Investment from Petrichor Healthcare Management, $5M of Convertible Debt to be Purchased Upon Closing
An additional $20 million to be funded upon the potential U.S. Food and Drug Administration (FDA) approval of PEDMARKTM by September 30, 2022 and satisfaction of other closing conditions. Fennec upon